Welcome to our dedicated page for Carecloud news (Ticker: CCLD), a resource for investors and traders seeking the latest updates and insights on Carecloud stock.
CareCloud, Inc. reports developments in AI-powered healthcare technology and revenue cycle management for medical practices and health systems. Company updates center on electronic health records, practice management, medical billing, patient experience management, business intelligence, digital health, and AI product portfolios including stratusAI, cirrusAI, and Marketware.
Recurring news themes include quarterly results, guidance, customer selections, product expansion into inpatient EHR, RCM, and analytics, and capital-structure actions involving credit facilities and preferred-stock matters. Updates also address cross-sell strategy, automation initiatives, conference presentations, and operational performance across its Healthcare IT and Medical Practice Management activities.
CareCloud (Nasdaq: CCLD) reported that Empower, its compliance business, supported a successful Medicare appeal reversing over $1 million in alleged overpayments for an experienced wound-care provider. An Administrative Law Judge ruled the advanced wound-care services were medically reasonable, necessary, and properly billed.
The case highlights Empower’s certified coding and documentation analysis, CareCloud’s AI-powered revenue cycle solutions used by over 45,000 providers, and aligns with CareCloud’s acquisition of Empower Healthcare & Compliance Partners, which closed on May 22, 2026.
CareCloud (Nasdaq: CCLD) announced that shareholders at the June 4, 2026 Annual Meeting overwhelmingly approved all proposals. These included re-electing Mahmud Haq and Cameron Munter to new two-year Board terms, approving executive compensation, the 2026 Equity Incentive Plan, and ratifying Tanner LLP as independent auditor for 2026.
CareCloud (Nasdaq: CCLD) acquired Empower Healthcare & Compliance Partners, a full-service healthcare compliance and advisory firm, in an asset purchase that closed May 22, 2026. Empower brings revenue integrity, M&A compliance, privacy and security, and compliance & ethics services to CareCloud’s AI-powered platform and more than 45,000 providers.
According to CareCloud, the deal creates a cross-selling opportunity, adds a new recurring revenue stream, is funded from operating cash flow, and is not expected to be material to 2026 financial results. Empower’s services reach CareCloud clients in Q2 2026, with AI-enabled SaaS solutions planned for the second half of 2026.
CareCloud (Nasdaq: CCLD) used its May 19, 2026 Analyst Day to outline four growth themes: an AI-first platform, a simplified common-stock structure, rising free cash flow, and a disciplined acquisition strategy.
The company redeemed all remaining Series B preferred stock on May 15, 2026 using part of a $50 million credit facility, eliminating about $140 million of preferred equity and roughly $13.5 million in annual preferred dividends. Free cash flow has increased about six-fold since 2023, with 2026 guidance of approximately $25 million, and related principal and interest obligations expected to be less than half of that amount.
CareCloud highlighted AI tools such as its Stratus AI Front Desk Agent, which now autonomously handles about three of every four inbound patient calls. Since its 2014 IPO, the company has completed more than 20 tuck-in acquisitions. Customers including Fox Rehabilitation, KabaFusion, and The Lung Center reported improvements in denial rates, bad debt, claim resolution, chart completion, and call scheduling tied to CareCloud’s solutions.
CareCloud (Nasdaq: CCLD) fully redeemed 100% of its 8.75% Series B Preferred Stock, funded by a new $50 million credit facility led by Citizens Bank with Provident Bank participation. The move replaces higher-cost preferred equity with lower-cost debt and simplifies the capital structure.
Since 2015, revenue grew from about $23 million to approximately $130 million expected in 2026, with over 20 acquisitions, more than 45,000 providers served, first full year of positive GAAP net income in 2025, and about $30 million expected 2026 annualized adjusted EBITDA.
CareCloud also maintains a $60 million ATM equity facility and plans to issue shares only at or above $5.00 per share.
CareCloud (Nasdaq: CCLD) will host its 2026 Analyst Day on May 19, 2026, at Nasdaq MarketSite, focusing on capital structure, AI strategy, and growth.
CareCloud closed a $50 million credit facility and prefunded about $41.6 million to fully redeem Series B Preferred Stock on May 15, reducing preferred equity and lowering its cost of capital without common shareholder dilution.
CareCloud (Nasdaq: CCLD) reported Q1 2026 revenue of $31.3M (up 13% YoY) and GAAP net income of $0.922M. Adjusted EBITDA was $5.4M. The company closed a $50M credit facility, announced full redemption of Series B preferred stock (scheduled May 15, 2026), launched AI products, and reaffirmed full-year 2026 guidance of $128–$132M revenue, $29–$31M adjusted EBITDA, and GAAP EPS $0.20–$0.23.
Management cited Medsphere integration costs and elevated amortization as near-term impacts and expects margin expansion later in 2026.
CareCloud (Nasdaq: CCLD) will report first quarter 2026 financial results before market open on May 7, 2026 and host a conference call at 8:30 a.m. ET.
Investors can join via live webcast and download slides at ir.carecloud.com/events. Audio-only dial‑in options and a replay available about three hours after the call.
CareCloud (Nasdaq: CCLD) reaffirmed its previously issued financial guidance after completing a capital structure simplification on April 16, 2026.
Key actions include closing a $50 million credit facility and redeeming 100% of Series B preferred stock. The company reports ~$130 million revenue and ~$30 million annualized adjusted EBITDA, citing improved financial flexibility and institutional support for its next growth phase.
CareCloud (Nasdaq: CCLD, CCLDO) closed a $50 million credit facility on April 13, 2026, with Citizens Bank and Provident Bank and will fully redeem 100% of its outstanding 8.75% Series B preferred stock on May 15, 2026.
The redemption covers 1,511,372 shares at a Total Redemption Price of $27.52 per share, eliminates roughly $3.2 million in annual preferred dividends, and simplifies the capital structure while preserving non-dilutive institutional financing and liquidity.